Echo Therapeutics, Inc., a diabetes management company developing a new needle-free Glocose Monitoring System, reports starting a new a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring product. The (tCGM System) study includes patients with Type 1 and Type 2 diabetes. The purpose of the study is to test the performance of its new one-piece, cost-effective biosensor. Echo expects to announce completed results of the study by the fourth quarter of 2009.

Echo’s pilot clinical study will enroll patients that have either type 1 or type 2 diabetes and will compare data obtained from its Symphony tCGM System with data from the “YSI Glucose Analyzer. The study will obtain about 900 data pairs for use in the analyses. The study will be blind to participating subjects and personnel working on the project and will include reference glucose measurements made at roughly 15 minute intervals for 24 hours.

Patrick T.